CD86 and neoplasm: Similarly, multiple pathways implicated in PKD (e.g., IFN-γ/JAK-STAT, TNF-α, NF-κB, PI3K, and HIF-1) drive PD-L1 and CD80/CD86 expression on tumor cells (10, 63–66).